Cover Image
Market Research Report

Viral Vector Manufacturing - Global Market Outlook (2017-2026)

Published by Stratistics Market Research Consulting Product code 825560
Published Content info 168 Pages
Delivery time: 2-3 business days
Price
Back to Top
Viral Vector Manufacturing - Global Market Outlook (2017-2026)
Published: March 1, 2019 Content info: 168 Pages
Description

According to Stratistics MRC, the Global Viral Vector Manufacturing Market is accounted for $227.63 million in 2017 and is expected to reach $1,013.00 million by 2026 growing at a CAGR of 18.0% during the forecast period. The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches are some of the factors propelling the market growth. However, the excessive cost of gene therapies and possible mutagenesis impede the market.

Viral Vector Manufacturing comprises the generation of these vectors, which then have to be purified in order to meet the quality attributes required for further use as gene delivery systems. Viral or non-viral vector methods are used the inefficient transfer of the therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.

On the basis of application, Gene Therapy segment holds the significant growth during the forecast period due to the availability of effective viral vector gene therapies for rare diseases & cancers, ongoing research activities on viral vector gene therapies.

Based on geography, North America holds the major market share during the forecast period owing to rise in research activities, a large number of regenerative medicine companies, increase in the prevalence of target diseases and availability of funds.

Some of the key players profiled in the Viral Vector Manufacturing Market include Spark Therapeutics, Uniqure, Kaneka Eurogentec, Regenxbio, Finvector Vision Therapies, Novasep, Massbiologics, Merck KGaA, Cobra Biologics, Fujifilm Holdings Corporation, Lonza, Brammer Bio, Oxford Biomedica and Thermo Fisher Scientific Inc.

Types Covered:

  • Adenoviral Vectors
  • Retroviral Vectors
  • Adeno-Associated Viral Vectors
  • Pox Virus
  • Cytomegalovirus
  • Other Types

Diseases Covered:

  • Human Disease
  • Veterinary Disease

Applications Covered:

  • Vaccinology
  • Gene Therapy

End Users Covered:

  • Research Institutes
  • Pharmaceutical and Biopharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Vector Manufacturing Market, By Type

  • 5.1 Introduction
  • 5.2 Adenoviral Vectors
  • 5.3 Retroviral Vectors
    • 5.3.1 Gamma-Retroviral Vectors
    • 5.3.2 Lentiviral Vectors
  • 5.4 Adeno-Associated Viral Vectors
  • 5.5 Pox Virus
  • 5.6 Cytomegalovirus
  • 5.7 Other Types
    • 5.7.1 Herpes Simplex Virus Vectors

6 Global Viral Vector Manufacturing Market, By Disease

  • 6.1 Introduction
  • 6.2 Human Disease
    • 6.2.1 Infectious Diseases
      • 6.2.1.1 Influenza
      • 6.2.1.2 Malaria
      • 6.2.1.3 Hepatitis
    • 6.2.2 Genetic Disorders
      • 6.2.2.1 Human Immunodeficiency Virus (HIV)
      • 6.2.2.2 Tuberculosis
    • 6.2.3 Cancer
    • 6.2.4 Other Human Diseases
  • 6.3 Veterinary Disease
    • 6.3.1 Avian Influenza
    • 6.3.2 Marek's Disease
    • 6.3.3 Infectious Bronchitis
    • 6.3.4 Peste des Petits Ruminants (PPR) Disease
    • 6.3.5 Other Veterinary Diseases
      • 6.3.5.1 Rabies
      • 6.3.5.2 Fibromuscular Dysplasia (FMD)
      • 6.3.5.3 Swine Influenza
      • 6.3.5.4 Equine Influenza
      • 6.3.5.5 Newcastle Disease

7 Global Viral Vector Manufacturing Market, By Application

  • 7.1 Introduction
  • 7.2 Vaccinology
    • 7.2.1 Multivalent Vaccines
    • 7.2.2 Multipathogen Vaccines
  • 7.3 Gene Therapy

8 Global Viral Vector Manufacturing Market, By End User

  • 8.1 Introduction
  • 8.2 Research Institutes
  • 8.3 Pharmaceutical and Biopharmaceutical Companies
  • 8.4 Other End Users

9 Global Viral Vector Manufacturing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Spark Therapeutics
  • 11.2 Uniqure
  • 11.3 Kaneka Eurogentec
  • 11.4 Regenxbio
  • 11.5 Finvector Vision Therapies
  • 11.6 Novasep
  • 11.7 Massbiologics
  • 11.8 Merck KGaA
  • 11.9 Cobra Biologics
  • 11.10 Fujifilm Holdings Corporation
  • 11.11 Lonza
  • 11.12 Brammer Bio
  • 11.13 Oxford Biomedica
  • 11.14 Thermo Fisher Scientific Inc.

List of Tables

  • 1 Global Viral Vector Manufacturing Market Outlook, By Region (2016-2026) ($MN)
  • 2 Global Viral Vector Manufacturing Market Outlook, By Type (2016-2026) ($MN)
  • 3 Global Viral Vector Manufacturing Market Outlook, By Adenoviral Vectors (2016-2026) ($MN)
  • 4 Global Viral Vector Manufacturing Market Outlook, By Retroviral Vectors (2016-2026) ($MN)
  • 5 Global Viral Vector Manufacturing Market Outlook, By Gamma-Retroviral Vectors (2016-2026) ($MN)
  • 6 Global Viral Vector Manufacturing Market Outlook, By Lentiviral Vectors (2016-2026) ($MN)
  • 7 Global Viral Vector Manufacturing Market Outlook, By Adeno-Associated Viral Vectors (2016-2026) ($MN)
  • 8 Global Viral Vector Manufacturing Market Outlook, By Pox Virus (2016-2026) ($MN)
  • 9 Global Viral Vector Manufacturing Market Outlook, By Cytomegalovirus (2016-2026) ($MN)
  • 10 Global Viral Vector Manufacturing Market Outlook, By Other Types (2016-2026) ($MN)
  • 11 Global Viral Vector Manufacturing Market Outlook, By Herpes Simplex Virus Vectors (2016-2026) ($MN)
  • 12 Global Viral Vector Manufacturing Market Outlook, By Disease (2016-2026) ($MN)
  • 13 Global Viral Vector Manufacturing Market Outlook, By Human Disease (2016-2026) ($MN)
  • 14 Global Viral Vector Manufacturing Market Outlook, By Infectious Diseases (2016-2026) ($MN)
  • 15 Global Viral Vector Manufacturing Market Outlook, By Genetic Disorders (2016-2026) ($MN)
  • 16 Global Viral Vector Manufacturing Market Outlook, By Cancer (2016-2026) ($MN)
  • 17 Global Viral Vector Manufacturing Market Outlook, By Other Human Diseases (2016-2026) ($MN)
  • 18 Global Viral Vector Manufacturing Market Outlook, By Veterinary Disease (2016-2026) ($MN)
  • 19 Global Viral Vector Manufacturing Market Outlook, By Avian Influenza (2016-2026) ($MN)
  • 20 Global Viral Vector Manufacturing Market Outlook, By Marek's Disease (2016-2026) ($MN)
  • 21 Global Viral Vector Manufacturing Market Outlook, By Infectious Bronchitis (2016-2026) ($MN)
  • 22 Global Viral Vector Manufacturing Market Outlook, By Peste des Petits Ruminants (PPR) Disease (2016-2026) ($MN)
  • 23 Global Viral Vector Manufacturing Market Outlook, By Other Veterinary Diseases (2016-2026) ($MN)
  • 24 Global Viral Vector Manufacturing Market Outlook, By Application (2016-2026) ($MN)
  • 25 Global Viral Vector Manufacturing Market Outlook, By Vaccinology (2016-2026) ($MN)
  • 26 Global Viral Vector Manufacturing Market Outlook, By Multivalent Vaccines (2016-2026) ($MN)
  • 27 Global Viral Vector Manufacturing Market Outlook, By Multipathogen Vaccines (2016-2026) ($MN)
  • 28 Global Viral Vector Manufacturing Market Outlook, By Gene Therapy (2016-2026) ($MN)
  • 29 Global Viral Vector Manufacturing Market Outlook, By End User (2016-2026) ($MN)
  • 30 Global Viral Vector Manufacturing Market Outlook, By Research Institutes (2016-2026) ($MN)
  • 31 Global Viral Vector Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2016-2026) ($MN)
  • 32 Global Viral Vector Manufacturing Market Outlook, By Other End Users (2016-2026) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Back to Top